Literature DB >> 8564253

Lack of involvement of bradykinin in the vascular sympathoinhibitory effects of angiotensin converting enzyme inhibitors in spontaneously hypertensive rats.

B Chauvin1, C Richer, J F Giudicelli.   

Abstract

1. The aim of this study was to investigate the contribution of endogenous bradykinin to the vascular sympathoinhibitory effects exerted by angiotensin I converting enzyme inhibitors (ACEIs) in the spontaneously hypertensive rat (SHR). 2. Adult SHRs were treated daily for 8 days with either perindopril (3 mg kg-1), or a selective angiotensin II AT1 receptor antagonist, losartan (10 mg kg-1) both given orally--these two doses being equipotent in inhibiting angiotensin I (AI)-induced vascular responses--or distilled water (controls). After pithing, the animals were instrumented for determination of blood pressure, heart rate, cardiac output, regional (renal, mesenteric, hindlimb) blood flows (pulsed Doppler technique) and corresponding vascular resistances. Afterwards, half of the animals of each group were given the selective bradykinin B2 receptor antagonist, icatibant, used in a dose (10 micrograms kg-1, i.v.) that achieved B2 receptor blockade, the other half received saline (10 microliters kg-1, i.v.). Haemodynamic responses to increasing frequencies of spinal cord stimulation were then measured. 3. Pressor and vasoconstrictor responses to AI were significantly and similarly reduced in both perindopril- and losartan-treated groups. Perindopril and losartan both decreased to a similar extent the pressor and vasoconstrictor responses to electrical stimulation of the spinal cord. 4. In the dose used, icatibant did not affect any of the investigated haemodynamic parameters in any of the experimental groups. Furthermore, icatibant did not affect the stimulation frequency-response curves in the control animals and did not modify the vascular sympathoinhibitory effects exerted by perindopril and by losartan. 5 Taken together, these results demonstrate that endogenous bradykinin does not, through B2 receptor activation, contribute to the vascular sympathoinhibitory effects of ACEIs in SHRs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8564253      PMCID: PMC1908974          DOI: 10.1111/j.1476-5381.1995.tb15058.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Bradykinin and postganglionic sympathetic transmission.

Authors:  K Starke; B A Peskar; K A Schumacher; H D Taube
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-08       Impact factor: 3.000

2.  An ultrasonic pulsed Doppler system for measuring blood flow in small vessels.

Authors:  C J Hartley; J S Cole
Journal:  J Appl Physiol       Date:  1974-10       Impact factor: 3.531

Review 3.  Repeated measurements and multiple comparisons in cardiovascular research.

Authors:  J Ludbrook
Journal:  Cardiovasc Res       Date:  1994-03       Impact factor: 10.787

4.  Interaction of angiotensin-converting enzyme inhibitors with the function of the sympathetic nervous system.

Authors:  D P Clough; M G Collis; J Conway; R Hatton; J R Keddie
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

5.  Converting enzyme inhibitor and saralasin infusion in rats. Evidence for an additional vasodepressor property of converting enzyme inhibitor.

Authors:  H Thurston; J D Swales
Journal:  Circ Res       Date:  1978-05       Impact factor: 17.367

6.  Converting enzyme inhibition in essential hypertension: the hypotensive response does not reflect only reduced angiotensin II formation.

Authors:  S L Swartz; G H Williams; N K Hollenberg; T J Moore; R G Dluhy
Journal:  Hypertension       Date:  1979 Mar-Apr       Impact factor: 10.190

7.  Attenuation by bradykinin of adrenergically-induced vasoconstriction in the isolated perfused kidney of the rabbit: relationship to prostaglandin synthesis.

Authors:  K U Malik; A Nasjletti
Journal:  Br J Pharmacol       Date:  1979-10       Impact factor: 8.739

8.  Effects of bradykinin B2 receptor antagonism on the hypotensive effects of ACE inhibition.

Authors:  H Bouaziz; Y Joulin; M Safar; A Benetos
Journal:  Br J Pharmacol       Date:  1994-11       Impact factor: 8.739

9.  Effects of converting enzyme inhibitors on angiotensin and bradykinin peptides.

Authors:  D J Campbell; A Kladis; A M Duncan
Journal:  Hypertension       Date:  1994-04       Impact factor: 10.190

10.  Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies.

Authors:  K Wirth; F J Hock; U Albus; W Linz; H G Alpermann; H Anagnostopoulos; S Henk; G Breipohl; W König; J Knolle
Journal:  Br J Pharmacol       Date:  1991-03       Impact factor: 8.739

View more
  1 in total

1.  Involvement of nitric oxide, but not prostaglandins, in the vascular sympathoinhibitory effects of losartan in the pithed spontaneously hypertensive rat.

Authors:  C Richer; V Domergue; M P Vincent; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.